-
Vyepti®
Vyepti® (eptinezumab-jjmr) is a monoclonal antibody infusion therapy approved for the preventive treatment of migraine in adults. Designed for patients who experience frequent or debilitating migraines, Vyepti® works at the neurological level to reduce migraine frequency, severity, and overall disease burden.
At Singlepoint Healthcare, Vyepti® infusions are administered in a comfortable, closely monitored environment, providing patients with reliable migraine prevention and personalized infusion care.
How Vyepti® Works
Vyepti® works by targeting calcitonin gene-related peptide (CGRP), a protein known to play a key role in migraine development. CGRP levels rise during migraine attacks, contributing to inflammation, pain signaling, and blood vessel changes in the brain.
By binding to CGRP and blocking its activity, Vyepti® helps prevent migraines before they start rather than treating pain after onset. Because it is delivered intravenously, Vyepti® begins working quickly and provides sustained migraine prevention over time.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | |
| Manufacturer | Lundbeck |
| Administered by | Infusion |
| Frequency | ~3 months |
| Length of Infusion | ~30 minutes |
| FDA Approval(s) | Migraine Prevention: Approved on February 21, 2020 |